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Background: Septic shock is a major healthcare problem with a high mortality rate that might be caused by
immunosuppression. Programmed cell death receptor-1 (PD-1) and programmed cell death receptor ligand-1
(PD-L1), which are co-inhibitory receptor molecules, participate in sepsis-induced immunosuppression. In this
study, we investigated which PD-1-related molecules can be used to evaluate the risk stratification and
prognosis of septic patients. Furthermore, we explored the prognostic significance of a combination of ideal
predictors and conventional clinical risk parameters in septic shock patients.
Methods: In total, 29 healthy controls, 59 septic patients, and 76 septic shock patients were enrolled in this study.
Considering that the focus of the research was on the second phase of sepsis, blood samples were obtained at days
3–4 after the onset of systemic inflammatory response syndrome (SIRS). PD-1 and PD-L1 expression were measured on
circulating CD4+ T cells, CD8+ T cells, and monocytes (PD-L1 only) by flow cytometry.
Results: Our results showed that only monocyte PD-L1 expression gradually increased, based on the increasing
severity of disease (P < 0.001). Similarly, multivariate logistic regression analysis showed that only monocyte PD-L1
expression was an independent predictor of 28-day mortality in septic shock patients. Area under the receiver
operating characteristic curve analysis of the combination of monocyte PD-L1 expression and conventional clinical
risk parameters indicated a more significant prognostic ability than analysis of each parameter alone.
Conclusion: Our study demonstrated that, among PD-1-related molecules, only monocyte PD-L1 expression after
3–4 days of sepsis was associated with risk stratification and mortality in septic patients. Furthermore, measurement of
monocyte PD-L1 expression was a promising independent prognostic marker for septic shock patients.
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Septic shock is a major healthcare problem with a high
mortality rate [1]. Early and aggressive support treat-
ment has not improved survival in patients with septic
shock [2]. Postmortem studies of septic patients
highlighted that immunosuppression may be a key cause* Correspondence: lcscyyy@163.com
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nonsurviving patients with septic shock died in the stage
of immunosuppression [5]. The immunosuppression
phase is characterized by increased lymphocyte apop-
tosis, increased numbers of regulatory T cells, increased
suppression of cytokine production, and decreased hu-
man leukocyte antigen-DR (HLA-DR) expression [6–9].
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sepsis-induced immunosuppression [4].
PD-1 is expressed on activated T cells, natural killer
cells, and B cells [10]. Its ligand, PD-L1, is broadly
expressed on hematopoietic and nonhematopoietic cells
[11]. The PD-1/PD-L1 pathway exerts inhibitory effects
by regulating T-cell activation, tolerance, and immuno-
pathology [12, 13]. Although many studies have explored
the roles of the PD-1/PD-L1 pathway in septic animals
and patients, few studies have explored the relationship
between PD-1-related molecules and the risk stratifica-
tion of septic patients, and evaluated which PD-1-related
molecules are useful biomarkers to predict mortality
during the immunosuppressive phase of septic shock. In
addition, most previous reports of PD-1-related mole-
cules during sepsis focused on single measurements of
immunosuppression. The correlation of PD-1-related
molecules with conventional clinical risk parameters
may be more useful for predicting 28-day mortality. In
this study, we evaluated whether PD-1 and PD-L1 ex-
pression on circulating CD4+ T cells, CD8+ T cells, and
monocytes (PD-L1 only) at days 3–4 of the onset of sep-
sis can be used to evaluate the risk stratification and
prognosis of septic patients. Furthermore, we explored
the prognostic significance of a combination of ideal




The patients in this study were from the emergency de-
partment (ED) of Beijing Chao-yang Hospital. There are
about 250,000 ED admissions per year in this university
teaching hospital. Patients admitted to the ED at days
1–2 after the onset of signs of systemic inflammatory
response syndrome (SIRS) were evaluated for possible
enrollment according to the inclusion and exclusion
criteria. The eligible patients were treated according
to the international guidelines for management of
septic shock [2]. The beginning of vasopressive ther-
apy was defined as the onset of the septic shock.
Considering the investigation’s focus on the second
phase of sepsis, blood samples were obtained at days
3–4 after the onset of SIRS [5, 14].
According to the diagnostic criteria of the 2001 SCCM/
ESICM/ACCP/ATS/SIS International Sepsis Definitions
Conference [15], sepsis was defined by an identifiable site
of infection, which was evidence of a systemic inflamma-
tory response (SIRS) manifested by at least two of the fol-
lowing criteria: (a) body temperature >38.5 °C or <36 °C;
(b) heart rate >90 beats per minute; (c) respiratory
rate >20 breaths per minute or PaCO2 <32 mmHg;
and (d) white cell count >12,000/mm3 or <4000/mm3,
or percentage of immature neutrophils >10 %. Septicshock was defined as sepsis-induced hypotension despite
adequate fluid resuscitation. Sepsis-induced hypotension
was defined as a systolic blood pressure (SBP) <90 mmHg
or mean arterial pressure (MAP) <70 mmHg or SBP de-
crease >40 mmHg or less than two standard deviations
below normal for age in the absence of other causes of
hypotension. According to the criteria of the International
Sepsis Forum Consensus Conference on Definitions of
Infection [16], the infection was defined on the basis of
clinical features, laboratory findings, and an imaging test.
The exclusion criteria were: (a) age less than 18 years;
(b) patients with HIV infection or cancer if they were
treated with a high dose of corticoids or if they pre-
sented with an aplasia (polymorphonuclear neutrophil
count of less than 0.5 G/L); (c) patients who died within
2 days of the onset of septic shock; (d) the signs of SIRS
occurred more than 3 days prior to admission, or patients
were transferred from another hospital; and (e) patients
who declined to consent.
Data collection
Clinical characteristics of patients, including age, gender,
past medical history, vital signs, and results of correlative
laboratory examinations, were recorded at days 3–4 after
the onset of septic shock. Sepsis-related organ failure as-
sessment (SOFA) score and simplified acute physiology
score II (SAPS II) were calculated according to related
clinical and demographic data. This study was approved
by the Beijing Chao-yang Hospital Ethics Committee.
Written informed consent was obtained from the pa-
tients and volunteers. Consents for patients who were
unable to provide consent were provided by first-degree
relatives. During follow-up the following data were
collected: comorbidities (chronic obstructive pulmonary
diseases, congestive heart failure, cerebrovascular dis-
ease, diabetes), and the outcome after 28 days (survival
or death).
Flow cytometry
Samples of peripheral blood were collected in ethylene-
diamine tetraacetic acid (EDTA) anticoagulant tubes.
The samples were transported to the laboratory at 4 °C
within 2 h. Erythrocytes were lysed and cells were
stained by a researcher who was blinded to the clinical
data. Antibodies were purchased from BD Bioscience
(San Jose, CA, USA) or eBioscience (San Diego, CA,
USA). According to the manufacturer’s recommenda-
tions monoclonal antibodies and their isotype controls
were used: BV421-labeled anti-PD1 (5 μl, clone EH12.1),
PE-labeled anti-PD-L1 (20 μl, clone M1H1), APC-H7 la-
beled anti-CD3 (5 μl, clone SK7), FITC-labeled anti-CD4
(5 μl clone OKT4), FITC-labeled anti-CD8 (20 μl, clone
RPA-T8), and APC-H7-labeled anti-CD14 (5 μl, clone
MφP9) per 100 μl of whole blood. Samples were run on
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analyzed using Gallios Software Version 1.0 (Beckman
Coulter, Inc.). Lymphocytes were gated by forward
scatter (FSC) and side scatter (SSC), and T-cells subsets
were further identified by CD3+ and CD4+ staining.
Monocytes were identified by CD14+ staining (Fig. 1). At
least 3000 cells were analyzed from each sample. The
threshold was defined using an isotype control. Results
are expressed as percentages and the mean of fluores-
cence intensities (MFI).Statistical analysis
The baseline characteristics were described as frequen-
cies, percentages, median and inter-quartile ranges.
Comparisons between groups were made using the
Pearson χ2 test for categorical data and the Mann-
Whitney test for continuous variables. For multi-
group comparisons, the Kruskal-Wallis test was ap-
plied. Age, white blood cell (WBC), lymphocytes,
SOFA score, and SAPS II were stratified using cutoff
values based on the population median [5]. PD-1 and
PD-L1 expressions were stratified using the optimal
threshold indicated by the receiver operating charac-
teristic (ROC) curve. Using cutoff values determined
by ROC curves, Kaplan-Meier survival curves were
established, and the log-rank test was applied for the
comparisons of survival distributions. Binary logistic
regression was used to identify the variables associ-
ated with 28-day mortality in patients with septic
shock. Variables with P < 0.15 in univariate analysisFig. 1 Representative flow dot plots of monocyte gating strategy and the
monocytes in different groups. The monocytes (gate B) were gated in the
plots of CD14 vs PD-L1 are representative of the percentage of monocyteswere conserved in the model. All statistical tests were
two-tailed, and P < 0.05 was considered statistically
significant. All data were analyzed using SPSS 19.0
software (SPSS Inc., Chicago, IL, USA).Results
Patient characteristics
Initially, 29 health controls, 59 septic patients, and 87
septic shock patients were admitted to the ED of Beijing
Chao-yang Hospital from June 2014 to September
2015. However, 11 septic shock patients were ex-
cluded because they died within 2 days of the onset
of septic shock. Thus, 76 septic shock patients were
enrolled in this study. Septic patients were divided
into the sepsis subgroup and septic shock subgroup
according to the disease severity. The demographic
and clinical characteristics of the patients are shown
in Tables 1 and 2. A comparison of survivors and
nonsurvivors showed significant differences in the
number of lymphocytes, SOFA score, SAPS II, and
comorbidities. Higher SOFA score and SAPS II indi-
cated a high level of severity. The major types of in-
fection were pneumonia (53.9 %) and urinary system
infection (USI) (23.7 %).Comparison of median levels of PD-1 and PD-L1
expression
PD-1 and PD-L1 expression was measured on circulat-
ing CD4+ T cells, CD8+ T cells, and monocytes (PD-L1
only) at days 3–4 after the onset of SIRS (Table 1).percentage of programmed cell death receptor ligand-1 (PD-L1) on
dot plots of side-scatter characteristics (SS) vs CD14. The multiple dot
in healthy control, survivor, and nonsurvivor groups
Table 1 Baseline characteristics of the patients
Parameters Control Sepsis Septic shock P value
Number 29 59 76 –
Age (years) 68 (66–75) 71 (66–78) 71 (61–78) 0.497
Male, n (%) 18 (62.1 %) 32 (54.2 %) 37 (48.7 %) 0.458
WBC (×109/L) 6.9 (5.6–7.9) 13.3 (10.9–17.8) 14.9 (11.8–17.2) <0.001
Lymphocyte (×109/L) 2.8 (2.4–3.1) 1.06 (0.73–1.63) 0.76 (0.54–1.07) <0.001
SOFA score 0 5 (3–7) 11 (9–14) <0.001
SAPS II 12 (12–15) 26 (24–32) 53 (46–60) <0.001
Percentage of PD-1+/CD4+ T cells (%) 26.2 (23.2–29.9) 34.1 (28.4–44.4) 38.2 (29.2–47.7) <0.001
MFI of PD-1 on CD4+ T cells 6.3 (5.8–6.8) 7.1 (5.2–9.2) 7.5 (6.0–9.4) 0.008
Percentage of PD-1+/CD8+ T cells (%) 22.6 (18.7–28.2) 31.6 (23.9–46.6) 36.5 (27.3–51.3) <0.001
MFI of PD-1 on CD8+ T cells 5.9 (4.8–6.6) 6.4 (4.2–7.5) 6.6 (4.9–8.4) 0.181
Percentage of PD-L1+/CD4+ T cells (%) 18.2 (12.3–22.6) 21.5 (16.5–30.5) 21.0 (9.3–30.6) 0.021
MFI of PD-L1 on CD4+ T cells 1.8 (1.6–2.2) 1.8 (1.6–2.6) 1.8 (1.5–2.0) 0.230
Percentage of PD-L1+/CD8+ T cells (%) 22.6 (17.1–26.2) 18.8 (14.9–37.6) 19.5 (10.3–37.4) 0.645
MFI of PD-L1 on CD8+ T cells 1.5 (1.4–1.7) 1.6 (1.2–2.1) 1.5 (1.4–1.8) 0.596
Percentage of monocytes expressing PD-L1 (%) 12.9 (10.4–15.3) 29.2 (12.1–43.9) 35.9 (20.4–54.7) <0.001
MFI of PD-L1 on monocytes 3.4 (3.0–3.9) 4.5 (2.2–7.5) 8.3 (7.7–9.7) <0.001
Type of infection, n (%)
Pneumonia 0 30 (50.8 %) 41 (53.9 %) 0.731
IAI 0 7 (11.8 %) 11 (14.5 %) 0.658
CNSI 0 5 (8.5 %) 6 (7.9 %) 0.903
USI 0 17 (28.8 %) 18 (23.7 %) 0.500
Number of comorbidities
≥1, n (%) 0 11 (18.6 %) 39 (51.3 %) <0.001
28-day mortality, n (%) 0 10 (16.9 %) 27 (35.5 %) 0.016
Data are shown as median and interquartile range unless otherwise indicated. Kruskal-Wallis one-way analysis of variance was performed for multi-group comparisons
CNSI central nervous system infection, IAI intra-abdominal infection, MFI mean of fluorescence intensities, PD-1 Programmed cell death receptor-1, PD-L1 programmed
cell death receptor ligand-1, SAPS II simplified acute physiology score II, SOFA sepsis-related organ failure assessment, USI urinary system infection, WBC white
blood cells
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culating PD-1/CD4+ T cells, PD-1/CD8+ T cells, and
monocytes expressing PD-L1 were significantly higher in
septic patients and septic shock patients (P < 0.05). Inter-
estingly, only the percentages of monocytes expressing
PD-L1 were obviously different between septic patients
and septic shock patients (P < 0.05). Similar results were
also observed when expressed as MFI.
Correlation of PD-L1 expression with SOFA score or SAPS II
in all patients
Spearman correlation analysis showed that the per-
centage of monocytes expressing PD-L1 in septic pa-
tients was positively correlated with SAPS II (r = 0.638;
P < 0.001) and SOFA score (r = 0.654; P < 0.001). MFI of
PD-L1 on monocytes was also positively correlated with
SAPS II (r = 0.653; P < 0.001) and SOFA score (r = 0.582;
P < 0.001).PD-1 and PD-L1 expression levels in survivors and
nonsurvivors in septic shock patients
Septic shock patients were divided into survivors and
nonsurvivors according to the 28-day mortality. In non-
survivors, the percentages of circulating PD-1/CD4+ T
cells, PD-1/CD8+ T cells, and monocytes expressing
PD-L1 were significantly higher in comparison with
survivors (Fig. 2; P < 0.05). Similar results were also
observed when expressed as MFI (Fig. 2; P < 0.05).
Value of PD-L1 expression for predicting 28-day mortality
in septic shock patients
The ROC curve analysis (area under the curve (AUC))
showed that the percentage of monocytes expressing
PD-L1 for predicting 28-day mortality was 0.729 (Table 3
and Fig. 3). ROC curve analysis showed that 44.2 % of
monocytes expressing PD-L1 was the optimal threshold
for predicting 28-day mortality in patients with septic
Table 2 Baseline characteristics of the patients with septic shock
Parameters Survivors Nonsurvivors Overall population P value
Number 49 27 76 –
Age (years) 73 (62–78) 70 (61–78) 71 (61–78) 0.765
Male, n (%) 22 (44.9 %) 15 (55.6 %) 37 (48.7 %) 0.792
WBC (×109/L) 14.9 (12.4–16.9) 13.3 (10.9–17.8) 14.9 (11.8–17.2) 0.641
Lymphocyte (×109/L) 0.78 (0.59–1.24) 0.65 (0.52–0.82) 0.76 (0.54–1.07) 0.046
SOFA score 11 (9–12) 14 (12–17) 11 (9–14) <0.001
SAPS II 50 (43–56) 60 (53–66) 53 (46–60) <0.001
Percentage of PD-1+/CD4+ T cells (%) 35.1 (28.5–44.8) 42.9 (34.9–49.0) 38.2 (29.2–47.7) 0.034
MFI of PD-1 on CD4+ T cells 7.0 (5.7–8.9) 8.8 (7.1–9.6) 7.5 (6.0–9.4) 0.036
Percentage of PD-1+/CD8+ T cells (%) 33.0 (24.8–44.3) 47.1 (30.3–53.9) 36.5 (27.3–51.3) 0.032
MFI of PD-1 on CD8+ T cells 5.9 (4.7–8.1) 7.8 (5.4–9.8) 6.6 (4.9–8.4) 0.033
Percentage of PD-L1+/CD4+ T cells (%) 16.4 (8.6–28.4) 22.1 (12.0–34.0) 21.0 (9.3–30.6) 0.295
MFI of PD-L1 on CD4+ T cells 1.9 (1.5–2.0) 1.8 (1.6–2.2) 1.8 (1.5–2.0) 0.961
Percentage of PD-L1+/CD8+ T cells (%) 23.2 (10.8–38.9) 12.9 (9.9–32.5) 19.5 (10.3–37.4) 0.204
MFI of PD-L1 on CD8+ T cells 1.6 (1.4–1.9) 1.5 (1.4–1.7) 1.5 (1.4–1.8) 0.378
Percentage of monocytes expressing PD-L1 (%) 28.9 (17.9–43.6) 53.9 (31.8–72.9) 35.9 (20.4–54.7) 0.001
MFI of PD-L1 on monocytes 8.2 (7.5–9.0) 9.1 (8.1–11.3) 8.3 (7.7–9.7) 0.012
Type of infection, n (%)
Pneumonia 27 (55.1 %) 14 (51.9 %) 41 (53.9 %) 0.786
IAI 8 (16.3 %) 3 (11.1 %) 11 (14.5 %) 0.781
CNSI 4 (8.2 %) 2 (7.4 %) 6 (7.9 %) 0.743
USI 10 (20.4 %) 8 (29.6 %) 18 (23.7 %) 0.366
Number of comorbidities
≥1, n (%) 21 (42.9 %) 18 (66.7 %) 39 (51.3 %) 0.047
Data are shown as median and interquartile range unless otherwise indicated
CNSI central nervous system infection, IAI intra-abdominal infection, MFI mean of fluorescence intensities, PD-1 Programmed cell death receptor-1, PD-L1 programmed
cell death receptor ligand-1, SAPS II simplified acute physiology score II, SOFA sepsis-related organ failure assessment, USI urinary system infection, WBC white
blood cells
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with a percentage of monocytes expressing PD-L1 higher
than 44.2 % had a lower probability of survival at day 28
than patients with lower PD-L1 levels (Fig. 4; P < 0.001).
Using a cutoff value of 44.2 % (for the percentage of
monocytes expressing PD-L1) for predicting 28-day
mortality in patients with septic shock, the sensitivity
was 68.0 %, specificity was 77.6 %, the positive predictive
value (PPV) was 65.7 %, and the negative predictive
value (NPV) was 79.2 %. Using a cutoff value of 8.44 (for
MFI of PD-L1 on monocytes) for predicting 28-day mor-
tality in patients with septic shock, the sensitivity was
66.7 %, specificity was 67.3 %, the PPV was 62.9 %, and
the NPV was 78.6 %.
PD-L1 expression as an independent predictor of 28-day
mortality in septic shock patients
Univariate and multivariate logistic regression were
used to identify PD-1-related molecules associatedwith 28-day mortality for patients with septic shock.
Multivariate logistic regression analysis showed that
only PD-L1 expression on monocytes was independ-
ently associated with 28-day mortality. The detailed
data are presented in Table 4.
Combination of PD-L1 expression with SOFA score or
SAPS II in septic shock patients
We further explored the prognostic significance of a
combination of independent predictors and conven-
tional clinical risk parameters in septic shock patients.
Interestingly, a combination of monocyte PD-L1 ex-
pression enhanced the ability of the SOFA score or
SAPS II to predict 28-day mortality in patients with
septic shock. The prognostic value of PD-L1 expres-
sion on monocytes in combination with SAPS II for
predicting 28-day mortality was significantly higher
than each parameter alone. The detailed data are pre-
sented in Table 3 and Fig. 3.
Fig. 2 Box-plot representation of programmed cell death receptor-1 (PD-1)-related molecules. Data are shown as box plot with medians
(lines inside boxes), 25th and 75th quartiles (limits of boxes); whiskers indicate the range. Programmed cell death receptor ligand-1 (PD-L1)
expression on monocytes and PD-1 expression on T cells (CD4+ and CD8+ T cells) were significantly increased in nonsurvivors (n = 27) in
comparison with survivors (n = 49) (a–f). MFI mean of fluorescence intensities
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Table 3 Area under the curve of various parameters for
predicting 28-day mortality in patients with septic shock
Variable AUC P value 95 % Confidence interval
Lower limit Upper limit
Percentage of monocytes
expressing PD-L1
0.729 0.001 0.607 0.852
MFI of PD-L1 on monocytes 0.681 0.009 0.548 0.813
SAPS II 0.768 <0.001 0.653 0.883
SOFA score 0.736 0.001 0.610 0.863
Percentage of PD-L1 on
monocytes + SAPS II
0.891 <0.001 0.807 0.976
MFI of PD-L1 on
monocytes + SAPS II
0.881 <0.001 0.797 0.965
Percentage of PD-L1 on
monocytes + SOFA score
0.829 <0.001 0.713 0.944
MFI of PD-L1 on
monocytes + SOFA score
0.799 <0.001 0.682 0.917
AUC area under the curve, MFI mean of fluorescence intensities, PD-L1
programmed cell death receptor ligand-1, SAPS II simplified acute physiology
score II, SOFA sepsis-related organ failure assessment
Fig. 3 Receive operating characteristic (ROC) curve for predicting
28-day mortality in septic shock patients. AUCs: the percentage of
PD-L1 on monocytes (dark blue line), 0.729; MFI of PD-L1 on
monocytes (green line), 0.681; SAPS II (pink line), 0.768; SOFA
score (brown line), 0.736; the percentage of PD-L1 on monocytes
in combination with SAPS II (C1, red line), 0.891; MFI of PD-L1 on
monocytes in combination with SAPS II (C2, yellow line), 0.881;
the percentage of PD-L1 on monocytes in combination with SOFA
score (C3, pale blue line), 0.829; and MFI of PD-L1 on monocytes in
combination with SOFA score (C4, gray line), 0.799. MFI mean of
fluorescence intensities, PD-L1 programmed cell death receptor
ligand-1, SAPS II simplified acute physiology score II, SOFA sepsis-
related organ failure assessment
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The present study demonstrated that, among PD-1-
related molecules, only monocyte PD-L1 expression
after 3–4 days of sepsis was valuable for the risk
stratification of septic patients. Monocyte PD-L1 ex-
pression was also an independent predictor of mortal-
ity in septic shock patients. Additionally, our study
demonstrated that monocyte PD-L1 expression com-
bined with clinical risk parameter (i.e., SAPS II) could
enhance the ability to predict 28-day mortality in pa-
tients with septic shock. To the best of our knowledge,
this is the largest number of patients with sepsis for which
PD-1-related molecules were explored, and our findings
may be useful for septic patient stratification and progno-
sis evaluation.
Sepsis is a complex pathophysiological process. It is
widely accepted that although there is a predominance
of the hyperinflammatory phase after sepsis initiation,
sepsis then rapidly develops a state of immunosuppres-
sion [17, 18]. Because of the application of antibiotics
and other aggressive treatments, many patients may sur-
vive the initial proinflammatory stage, but eventually die
later in a state of immunosuppression [18, 19]. PD-1 and
its ligand PD-L1 are thought to play major roles in im-
munosuppressive mechanisms. Blockade of the PD-1/
PD-L1 inhibitory pathway has been successfully used in
cancer and septic animals, and may have similar benefi-
cial effects in septic shock patients [20–23]. Since sepsis-
induced immunosuppression may play an important role
in mortality during sepsis, there is interest in identifying
patients with sepsis who may benefit from anti-PD-1
or anti-PD-L1 antibody therapy. Our finding may be
useful for subsequent studies of PD-1/PD-L1 blockade
in sepsis.
Although previous studies showed that increased PD-1
expression on T cells and monocyte PD-L1 expression
were associated with increased occurrence of mortality
and nosocomial infections [24, 25], we observed that
there were no differences in PD-1 expression on T cells
between septic patients and septic shock patients, and
also that it was not independently associated with 28-
day mortality in patients with septic shock. Therefore,
PD-1 expression on T cells may be not a reliable “danger
signal” for immunosuppression in septic patients. Inter-
estingly, we observed that monocyte PD-L1 expression
was valuable for the risk stratification of septic patients,
and that it was an independent predictor of mortality. In
that sense, monocyte PD-L1 expression may be useful
for patient stratification in clinical trials attempting to
boost the immune system in septic patients. Patients
with high levels of monocytes expressing PD-L1 should
be considered as immunosuppressed, which should be
taken into consideration regarding potentially deleteri-
ous effects.
Fig. 4 Survival curves of patients with septic shock according to the percentage of monocytes expressing PD-L1 (a) and MFI of PD-L1 on
monocytes (b). MFI mean of fluorescence intensities, PD-L1 programmed cell death receptor ligand-1
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and anti-PD-L1 antibodies could inhibit lymphocyte
apoptosis, reverse immune dysfunction, attenuate organ
dysfunction, and improve survival in a murine model of
sepsis [21, 25, 26]. In that sense, PD-1 and PD-L1 were
ideal targets to restore immune status in sepsis. The rea-
sons may be due to the fact that PD-L1 plays a major
role in the PD-1/PD-L1 pathway by exerting inhibitory
effects, while PD-1 is regarded as an auxiliary part of
that process. Previous mechanistic studies of PD-L1 pro-
vided several lines of evidence in support of this point:
PD-L1 blockage altered plasma cytokine levels, but PD-1
blockage did not [20, 25]. Our study showed that PD-L1
expression on monocytes was independently associated
with 28-day mortality in patients with septic shock, but
PD-1 on T cells was not; more studies are still needed to
certify this conclusion.Table 4 Logistic regression analysis of independent factors for 28-d
Variable B SE Wald
Percentage of monocytes expressing PD-L1 1.943 0.745 6.81
Lymphocytes 0.088 0.794 0.01
SOFA score 1.550 0.687 5.09
SAPS II 1.558 0.723 4.64
Number of comorbidities 1.887 0.726 6.76
Constant −4.133 0.918 20.25
PD-L1 programmed cell death receptor ligand-1, SAPS II simplified acute physiologyAnother intriguing finding of our study was that a
combination of monocyte PD-L1 expression with SAPS
II or SOFA score significantly enhanced the accuracy of
predicting 28-day mortality in patients with septic shock.
The optimized information provided by the use of com-
bined markers was clearly illustrated in our study. Con-
ventional clinical risk parameters indicated the severity
of disease. The levels of co-inhibitory receptor molecules
indicated the degree of immunosuppression that is char-
acteristic of an inefficient clearance of invasive microbial
pathogens. Combination of monocyte PD-L1 expression
and conventional clinical risk parameters may be opti-
mal candidates for predicting the prognosis of septic
shock. Of particular importance, we demonstrated
that monocyte PD-L1 expression combined with SAPS
II was the best factor for predicting 28-day mortality
in septic shock patients. These results suggested thatay mortality in patients with septic shock
P value Odds ratio 95 % confidence interval for EXP(B)
Lower limit Upper limit
1 0.009 6.981 1.622 30.041
2 0.912 1.092 0.230 5.173
1 0.024 4.713 1.226 18.117
6 0.031 4.749 1.152 19.584
1 0.009 6.598 1.591 27.352
6 0.000 0.016
score II, SOFA sepsis-related organ failure assessment
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of clinical markers to evaluate the prognosis of septic
shock patients.
Some limitations need to be considered in our study.
First, the sample size was relatively small, and it was a
single-center study. The current study findings should
be confirmed by a multicenter study. Second, dynamic
changes in the levels of monocyte PD-L1 expression re-
main targets for future studies. Third, because of the dif-
ferences in the brand of flow cytometer used in different
institutions, the cutoff values of PD-L1 on monocytes to
predict poor outcome may be different. Therefore,
similar to monocyte HLA-DR measurement [27], it is
necessary to establish a standard protocol in different in-
stitutions. Previous studies have demonstrated that low
levels of monocyte HLA-DR expression were associated
with impairment of monocytic cellular functions [28, 29].
Correlation of PD-L1 values with HLA-DR expression
may provide more useful information.
Conclusions
In conclusion, among PD-1-related molecules only
monocyte PD-L1 expression after 3–4 days of sepsis is
associated with risk stratification and mortality in septic
patients. Furthermore, measurement of monocyte PD-L1
expression was a promising independent prognostic
marker for septic shock patients.
Abbreviations
AUC: area under the curve; ED: emergency department; EDTA: ethylenediamine
tetraacetic acid; FSC: forward scatter; HLA-DR: human leukocyte antigen-DR;
MAP: mean arterial pressure; MFI: mean of fluorescence intensities;
NPV: negative predictive value; PD-1: programmed cell death receptor-1;
PD-L1: programmed cell death receptor ligand-1; PPV: positive predictive
value; ROC: receiver operating characteristic curve; SAPS II: simplified acute
physiology score II; SBP: systolic blood pressure; SIRS: system inflammatory
response syndrome; SOFA: Sepsis-related organ failure assessment;
SSC: side scatter; USI: urinary system infection; WBC: white blood cell.
Competing interests
The authors declare they have no competing interests.
Authors’ contributions
CS-L conceived and designed the study, and was involved in drafting the
manuscript and provided research funding. YF, HY, LZ, and ZJ collected data
and critically revised the manuscript. RS collected and analyzed data,
performed statistical analysis, and drafted and critically revised the manuscript.
All authors gave final approval for manuscript publication and agree to be
accountable for all aspects of this work.
Authors’ information
C-SL is a specialist of critical disease and the chief of the Emergency
Department of Beijing Chao-yang Hospital. RS, YF, HY, LZ, and ZJ are
graduate students of Emergency Medicine who are conducting a study
of sepsis.
Acknowledgements
The study was conducted thanks to the helpful contributions of the ED staff
and Biochemistry Laboratory staff.
Received: 5 December 2015 Accepted: 19 April 2016References
1. Rivers E, Nguyen B, Havstad S, Ressler J, Muzzin A, Knoblich B, et al. Early
goal-directed therapy in the treatment of severe sepsis and septic
shock. N Engl J Med. 2001;345:1368–77.
2. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al.
Surviving sepsis campaign: international guidelines for management of
severe sepsis and septic shock: 2012. Intensive Care Med. 2013;39(2):165–228.
3. Torgersen C, Moser P, Luckner G, Mayr V, Jochberger S, Hasibeder WR, et al.
Macroscopic postmortem findings in 235 surgical intensive care patients
with sepsis. Anesth Analg. 2009;108:1841–7.
4. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al.
Immunosuppression in patients who die of sepsis and multiple organ
failure. JAMA. 2011;306:2594–605.
5. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, et al. Persisting
low monocyte human leukocyte antigen-DR expression predicts mortality in
septic shock. Intensive Care Med. 2006;32:1175–83.
6. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg Jr RE, Hui JJ, Chang KC,
et al. Sepsis-induced apoptosis causes progressive profound depletion of B
and CD4+ T lymphocytes in humans. J Immunol. 2001;166:6952–63.
7. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, et al.
Increased circulating regulatory T cells (CD4(+)CD25(+)CD127(–))
contribute to lymphocyte anergy in septic shock patients. Intensive
Care Med. 2009;35:678–86.
8. Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD-1
expression by macrophages plays a pathologic role in altering microbial
clearance and the innate inflammatory response to sepsis. Proc Natl Acad
Sci U S A. 2009;106:6303–8.
9. Landelle C, Lepape A, Voirin N, Tognet E, Venet F, Bohé J, et al. Low
monocyte human leukocyte antigen-DR is independently associated
with nosocomial infections after septic shock. Intensive Care Med.
2010;36:1859–66.
10. Agata Y, Kawasaki A, Nishimura H, Ishida Y, Tsubata T, Yagita H, et al.
Expression of the PD-1 antigen on the surface of stimulated mouse T
and B lymphocytes. Int Immunol. 1996;8:765–72.
11. Sharpe AH, Wherry EJ, Ahmed R, Freeman GJ. The function of programmed
cell death 1 and its ligands in regulating autoimmunity and infection.
Nat Immunol. 2007;8:239–45.
12. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical
application. Int Immunol. 2007;19:813–24.
13. Nurieva RI, Liu X, Dong C. Yin-Yang of costimulation: crucial controls of
immune tolerance and function. Immunol Rev. 2009;229:88–100.
14. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel
understanding of the disorder and a new therapeutic approach. Lancet
Infect Dis. 2013;13(3):260–8.
15. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, et al.
International Sepsis Definitions Conference: 2001 SCCM/ESICM/ACCP/
ATS/SIS International sepsis definitions conference. Intensive Care Med.
2003;29(4):530–8.
16. Calandra T, Cohen J. The international sepsis forum consensus conference
on definitions of infection in the intensive care unit. Crit Care Med.
2005;33:1538–48.
17. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J
Med. 2003;348:138–50.
18. Munford RS, Pugin J. Normal responses to injury prevent systemic
inflammation and can be immunosuppressive. Am J Respir Crit Care Med.
2001;163:316–21.
19. Monneret G, Venet F, Pachot A, Lepape A. Monitoring immune
dysfunctions in the septic patient: a new skin for the old ceremony.
Mol Med. 2008;14:64–78.
20. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, et al. PD-L1 blockade improves
survival in experimental sepsis by inhibiting lymphocyte apoptosis and
reversing monocyte dysfunction. Crit Care. 2010;14(6):R220.
21. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS.
Delayed administration of anti-PD-1 antibody reverses immune dysfunction
and improves survival during sepsis. J Leukoc Biol. 2010;88(2):233–40.
22. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF,
et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med. 2012;366:2443–54.
23. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety
and activity of anti-PD-L1 antibody in patients with advanced cancer.
N Engl J Med. 2012;366:2455–65.
Shao et al. Critical Care  (2016) 20:124 Page 10 of 1024. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, et al.
Programmed death-1 levels correlate with increased mortality, nosocomial
infection and immune dysfunctions in septic shock patients. Crit Care.
2011;15(2):R99.
25. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, et al. Upregulation of programmed
death-1 on T cells and programmed death ligand-1 on monocytes in septic
shock patients. Crit Care. 2011;15(1):R70.
26. Zhu W, Bao R, Fan X, Tao T, Zhu J, Wang J, et al. PD-L1 blockade attenuated
sepsis-induced liver injury in a mouse cecal ligation and puncture model.
Mediators Inflamm. 2013;2013:361501.
27. Docke WD, Hoflich C, Davis KA, Rottgers K, Meisel C, Kiefer P, et al.
Monitoring temporary immunodepression by flow cytometric measurement of
monocytic HLA-DR expression: a multicenter standardized study. Clin Chem.
2005;2005(51):2341–7.
28. Astiz M, Saha D, Lustbader D, Lin R, Rackow E. Monocyte response to
bacterial toxins, expression of cell surface receptors, and release of anti-
inflammatory cytokines during sepsis. J Lab Clin Med. 1996;128:594–600.
29. Manjuck J, Saha DC, Astiz M, Eales LJ, Rackow EC. Decreased response to
recall antigens is associated with depressed co-stimulatory receptor
expression in septic critically ill patients. J Lab Clin Med. 2000;135:153–60.•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
